Shares in Basilea Pharmaceutica AG hit an all-time high on the Swiss Stock Exchange in Zurich last Friday of CHF240 (US$192), on good news about its broad-spectrum cephalosporin antibiotic ceftobiprole. Research analysis showed that ceftobiprole attained the primary endpoint of statistical non-inferiority versus a comparator combination therapy in a Phase III pivotal trial in patients with complicated skin and skin structure infection (cSSSI). (BioWorld International)
Shares in Basilea Pharmaceutica AG hit an all-time high on the Swiss Stock Exchange in Zurich last Friday of CHF240 (US$192), on good news about its broad-spectrum cephalosporin antibiotic ceftobiprole. Research analysis showed that ceftobiprole attained the primary endpoint of statistical non-inferiority versus a comparator combination therapy in a Phase III pivotal trial in patients with complicated skin and skin structure infection (cSSSI). (BioWorld International)
BioInvent International AB added $15 million to its coffers and could earn up to $175 million more in milestones from an agreement with Genentech Inc. to co-develop its preclinical monoclonal antibody BI-204, which is in development for prevention of acute coronary syndrome. (BioWorld Today)
BioInvent International AB added $15 million to its coffers and could earn up to $175 million more in milestones from an agreement with Genentech Inc. to co-develop its preclinical monoclonal antibody BI-204, which is in development for prevention of acute coronary syndrome. (BioWorld Today)
